Cluster #6, with poor treatment responses to triple-combo therapy, was characterized by older age at disease onset, increased levels of CRP and KL-6, and hypoxia at diagnosis, which were reported as poor prognostic factors in patients with myositis-associated ILD (9, 11). Here, MUC1 is linked to interstitial lung disease.